Latest Breaking News On - Anticipated milestones - Page 5 : comparemela.com

Bionomics (BNOX) Issues Review of 2023 and of 2024 Plans

Bionomics (BNOX) Issues Review of 2023 and of 2024 Plans
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSpyros papapetropoulosBionomics or companyMerck co incNicotinic acetylcholine receptor programClinical programBionomics limited nasdaqBionomics limitedPan navSocial anxiety disorderPost traumatic stress disorderAllosteric modulatorsAcetylcholine receptor programInc theAustralian stock exchangeAnticipated milestones

Bionomics Provides a Review of 2023 and of 2024 Plans

Bionomics Provides a Review of 2023 and of 2024 Plans
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSouth australiaUnited kingdomRajeev chandraKevin gardnerChris calabreseSpyros papapetropoulosMerck co incUs food drug administrationBionomics limited nasdaqInvestor centerBionomics or companyClinical programExchange commissionNicotinic acetylcholine receptor programCompany annual report on form

Insmed Provides Business Update at 42nd Annual J P Morgan Healthcare Conference

ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net.

New jerseyUnited statesSan franciscoWill lewisMandy faheyPharma gmbEleanor barisserBryan dunnData safety monitoring committeeRegional poison control centerInsmed incorporatedDrug administrationPrnewswire insmed incorporated nasdaqStage researchCorporate communicationsCompany annual report on form

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track .

United statesSan diegoStevena shallcrossChris calabreseInstitut catalaRicard mesiaMd institut catalTheriva biologicsEuropean society for medical oncologySociety for immunotherapy of cancerCompany annual report on formLifesci advisorsNet loss attributable to theriva biologics incOncologia catalan institute of oncologyUniversity of pennsylvaniaPancreatic ductal adenocarcinoma

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October.

Eric siemersDaniel oconnellAlex braunDrug administrationClinical developmentAcumen pharmaceuticals incDevelopment rd expensesExchange commissionDanielo connellChief executive officerAnticipated milestonesClinical trialsChief medical officerFast trackAcumen pharmaceuticalsPrivate securities litigation reform act